7KVI

Human CYP3A4 bound to an inhibitor

7KVI の概要

• エントリーDOI: 10.2210/pdb7kvi/pdb
• 分子名称: Cytochrome P450 3A4, PROTOPORPHYRIN IX CONTAINING FE, GLYCEROL, ... (5 entities in total)
• 機能のキーワード: cyp3a4, inhibitor, complex, oxidoreductase, oxidoreductase-oxidoreductase inhibitor complex, oxidoreductase/oxidoreductase inhibitor
• 由来する生物種: Homo sapiens (Human)
• タンパク質・核酸の鎖数: 1
• 化学式量合計: 57000.12

構造登録者

Sevrioukova, I. (登録日: 2020-11-28, 公開日: 2021-01-20, 最終更新日: 2023-10-18)

主引用文献

Samuels, E.R.,Sevrioukova, I.F.
Rational Design of CYP3A4 Inhibitors: A One-Atom Linker Elongation in Ritonavir-Like Compounds Leads to a Marked Improvement in the Binding Strength.
Int J Mol Sci, 22:-, 2021

PubMed Abstract: Inhibition of the major human drug-metabolizing cytochrome P450 3A4 (CYP3A4) by pharmaceuticals and other xenobiotics could lead to toxicity, drug-drug interactions and other adverse effects, as well as pharmacoenhancement. Despite serious clinical implications, the structural basis and attributes required for the potent inhibition of CYP3A4 remain to be established. We utilized a rational inhibitor design to investigate the structure-activity relationships in the analogues of ritonavir, the most potent CYP3A4 inhibitor in clinical use. This study elucidated the optimal length of the head-group spacer using eleven (series V) analogues with the R/R side-groups as phenyls or R-phenyl/R-indole/naphthalene in various stereo configurations. Spectral, functional and structural characterization of the inhibitory complexes showed that a one-atom head-group linker elongation, from pyridyl-ethyl to pyridyl-propyl, was beneficial and markedly improved K, IC and thermostability of CYP3A4. In contrast, a two-atom linker extension led to a multi-fold decrease in the binding and inhibitory strength, possibly due to spatial and/or conformational constraints. The lead compound, , was among the best inhibitors designed so far and overall, the strongest binder (K and IC of 0.007 and 0.090 µM, respectively). was the fourth structurally simpler inhibitor superior to ritonavir, which further demonstrates the power of our approach.

PubMed: 33467005
DOI: 10.3390/ijms22020852

実験手法

X-RAY DIFFRACTION (2.55 Å)